Research any topic before you write.
Find related topics. | Discover entities. | See connections. | Build a topical map.
Macitentan, sold under the brand name Opsumit, is an endothelin receptor antagonist developed by Actelion and approved for the treatment of pulmonary arterial hypertension (PAH). Macitentan is a dual endothelin receptor antagonist, meaning that it acts as an antagonist of two endothelin (ET) receptor subtypes, ETA and ETB. However, macitentan has a…
Art, Pharmacokinetics & Adverse effects
Explore the main themes, entities and connections around Macitentan. Start with the topic map, then use the sections below for research and deeper semantic analysis.
Start with a few of the strongest sections from the source topic. These are research directions, not a list of keywords you must use.
High-confidence facts extracted from structured source data. Use them as anchors for further research.
Browse the full topic structure. Each item opens a new analysis centered on that subject.
Deeper signals for content research, entity SEO and topical coverage. The plain-language headings explain what each technical view is useful for.
See the strongest relationship patterns around the current topic before diving into the raw triples.
Use these terms to understand the vocabulary surrounding the topic, not as a checklist for keyword stuffing.
endothelin et receptor receptors eta etb arterial cells et-1 pulmonary antagonist smooth muscle half-life plasma pah compared approved name opsumit
| Subject | Predicate | Object | Confidence | Src |
|---|---|---|---|---|
| Macitentan | 3D model (JSmol) | Interactive image | 1.00 | infobox |
| Macitentan | AHFS/Drugs.com | Monograph | 1.00 | infobox |
| Macitentan | ATC code | C02KX04 (WHO) | 1.00 | infobox |
| Macitentan | CAS Number | 441798-33-0 | 1.00 | infobox |
| Macitentan | ChEBI | CHEBI:76607 | 1.00 | infobox |
| Macitentan | ChEMBL | ChEMBL2103873 | 1.00 | infobox |
| Macitentan | ChemSpider | 13134960 | 1.00 | infobox |
| Macitentan | CompTox Dashboard (EPA) | DTXSID50196063 | 1.00 | infobox |
| Macitentan | DrugBank | DB08932 | 1.00 | infobox |
| Macitentan | Excretion | 2/3 urine, 1/3 faeces | 1.00 | infobox |
| Macitentan | Formula | C19H20Br2N6O4S | 1.00 | infobox |
| Macitentan | KEGG | D10135 | 1.00 | infobox |
| Macitentan | Legal status | AU: S4 (Prescription only) | 1.00 | infobox |
| Macitentan | Legal status | US: ℞-only | 1.00 | infobox |
| Macitentan | Legal status | EU: Rx-only | 1.00 | infobox |
| Macitentan | License data | US DailyMed: Macitentan | 1.00 | infobox |
| Macitentan | MedlinePlus | a615033 | 1.00 | infobox |
| Macitentan | Metabolism | Hydrolysis, oxidation (CYP3A4) | 1.00 | infobox |
| Macitentan | Molar mass | 588.28 g·mol−1 | 1.00 | infobox |
| Macitentan | Other names | ACT-064992 | 1.00 | infobox |
| Macitentan | Pregnancy category | AU: X (High risk) | 1.00 | infobox |
| Macitentan | PubChem CID | 16004692 | 1.00 | infobox |
| Macitentan | Routes of administration | By mouth | 1.00 | infobox |
| Macitentan | Trade names | Opsumit | 1.00 | infobox |
| Macitentan | UNII | Z9K9Y9WMVL | 1.00 | infobox |
| Macitentan | is a | dual endothelin receptor antagonist | 0.90 | text |
These clusters group vocabulary that occurs around closely connected concepts in the source material.
Bridges can reveal useful research angles that are easy to miss in a flat list of related terms.